The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

EMBO REPORTS, published by WILEY, is a premier journal in the fields of Biochemistry, Genetics, and Molecular Biology, recognized for its rigorous peer-review process and impactful scientific contributions. Established in the year 2000 in the United Kingdom, this journal has maintained a stellar reputation, reflected in its consistent positioning within the Q1 category across these disciplines as of 2023. EMBO REPORTS excels in disseminating high-quality and timely research that addresses fundamental questions and challenges in molecular biology and genetics, making it an invaluable resource for researchers, professionals, and students. With impressive Scopus rankings, including Genetics at the 32nd rank and a 90th percentile placement, it fosters an environment for scholarly exchange and advances in knowledge. While Open Access options are not available, the journal continues to enhance its impact through traditional subscription models, thereby maintaining wide visibility in the scientific community. Its ongoing evolution promises continued relevance and influence until at least 2024.

The Journal of Genetics and Genomics, published by SCIENCE PRESS in China, stands as a significant contributor to the fields of Genetics and Molecular Biology. With an ISSN of 1673-8527 and E-ISSN 1873-5533, this esteemed journal has achieved a remarkable reputation, holding a prestigious Q1 ranking in both Genetics and Molecular Biology as of 2023. This journal not only showcases pioneering research but also fosters vital discussions on contemporary challenges and innovations within genomic sciences. As part of its commitment to facilitating scientific advancement, the journal encompasses a range of research articles, reviews, and short communications, all aiming to illuminate the complexities of genetic structures and functions from 2007 to 2024. Researchers, professionals, and students alike are encouraged to engage with its content, which ranks favorably in Scopus—placing it within the top tier of its categories. Join the community of academic excellence and explore the latest findings that shape our understanding of genomics.

CYTOTHERAPY is a distinguished journal published by Elsevier Science Ltd, focusing on the critical fields of cell therapy, transplantation, and regenerative medicine. Since its inception in 1999, the journal has established itself as a vital resource for researchers and practitioners, contributing significantly to advancements in Cancer Research, Cell Biology, Genetics, Immunology, and Oncology. With an impressive range of Q2 rankings across multiple categories and a remarkable Q1 standing in Transplantation for 2023, CYTOTHERAPY delivers high-impact research that addresses the evolving challenges in these fields. While the journal does not offer open access, it remains a reputable avenue for disseminating pivotal studies and reviews that push the boundaries of cell-based therapies. Researchers, clinicians, and students alike will find CYTOTHERAPY an indispensable platform to stay abreast of the latest discoveries and innovations that are shaping the future of medical science.

The CRISPR Journal, published by MARY ANN LIEBERT, INC, is a pioneering platform dedicated to advancing the field of genetics and biotechnology through innovative research focused on CRISPR technology and its diverse applications. With an impressive Q1 ranking in both Biotechnology and Genetics for 2023, this journal is positioned among the leading publications in its field, showcasing groundbreaking studies from 2019 to 2024. While currently utilizing a subscription model, the journal's commitment to open science is reflected in its efforts to make high-quality research accessible to researchers, professionals, and students. The CRISPR Journal facilitates the dissemination of knowledge related to genomic editing technologies, fostering collaboration and advancing the understanding of gene manipulation, therapeutic techniques, and agricultural innovations. As a valuable resource for cutting-edge developments in the biochemistry and genetics landscape, this journal is essential for those seeking to stay at the forefront of CRISPR research and applications.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

CURRENT ISSUES IN MOLECULAR BIOLOGY, published by MDPI, serves as an essential forum for researchers and professionals in the rapidly evolving field of molecular biology. Established in 1999 and operating under an Open Access model, this journal not only shares high-quality research but also encourages a vibrant exchange of ideas across various disciplines, including medicine and microbiology. With an impressive trajectory leading into 2024, it has earned its place in the Q2 quartile for both Medicine (miscellaneous) and Microbiology, emphasizing its relevance and impact in these areas. The journal’s commitment to disseminating cutting-edge findings is reflected in its diverse coverage of topics, from molecular genetics to microbial interactions. Operating from its home base in Basel, Switzerland, CURRENT ISSUES IN MOLECULAR BIOLOGY is positioned to contribute significantly to the academic landscape, making it indispensable for those seeking to advance their understanding and research within the life sciences.

Molecular Genetics & Genomic Medicine, published by WILEY, is an esteemed and open-access journal that has been a prominent source of knowledge in the fields of genetics and molecular biology since its establishment in 2013. With an ISSN of 2324-9269, it aims to provide a platform for the dissemination of novel findings and innovative research that pushes the boundaries of genomics and its clinical applications. The journal holds a Q3 categorization in Genetics, Clinical Genetics, and Molecular Biology, reflecting its growing influence in these disciplines, as evidenced by its Scopus rankings. Researchers, professionals, and students alike will find valuable insights and advancements in genomic medicine, making this journal an essential resource for those dedicated to the understanding and application of genetic and molecular research in healthcare. Located at 111 River St, Hoboken, NJ, Molecular Genetics & Genomic Medicine continues to foster a global dialogue within the scientific community, ensuring accessible knowledge for all.

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.